

Synthesis of α -[5-(2-,3-, and 4-Pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylhydrazides and Related Compounds.

** I. MIR, M.T. SIDDIQUI AND A.M. * COMRIE

Pakistan Council of Scientific and Industrial Research, Peshawar, Pakistan.

**Department of Pharmacy, University of Strathclyde, George Street, Glasgow, U.K.*


(Received 8th August 1989, revised 28th December, 1989)

Summary: Potentially biologically active 2,5-disubstituted oxadiazoles have been prepared with a view to testing them against INH-resistant strains of *Mycobacterium tuberculosis*.

In the earlier papers [1-4], we reported the syntheses of α -[5-(2-furyl)-1,2,4-triazol-3-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,2,4-triazol-3-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,2,4-triazol-3-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,2,4-triazol-3-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide, α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide and related compounds. Some of these compounds have been found to exhibit significant activity against *M. tuberculosis* strains H37R_v and Academic in Peizer and Schectar medium compared with isoniazide.

Although some of the above compounds have been found to possess marked antitubercular activity, they proved inactive against INH-resistant strains of *M. tuberculosis*. Since incorporation of the nitro group into the ring confers enhanced antibacterial activity it was considered worthwhile to synthesize α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide and related compounds for bacteriological examination. When these compounds were tested, they were found to be less active than the corresponding compounds unsubstituted in the furan ring. The reduced activity of these nitro-compounds has been attributed to their unfavourable lipid-water partition coefficients. It seemed likely that the replacement of the nitro-furan ring in α -[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazide and related compounds with

a pyridine ring would improve the lipid-water partition coefficient of these compounds, and hence their anti-tubercular activity. Furthermore, a number of pyridyl-1,3,4-oxadiazol-2-thiols have been prepared and shown to be both leprostatic and tuberculostatic [5]. Hence it was considered worthwhile to synthesize α -[5-(2-,3-, and 4-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemicarbazides, thiosemicarbazides and some salicylidene derivatives for testing against INH resistant strains of *M. tuberculosis*, H37R_v and Academia. With a view to synthesizing these compounds, the intermediate pyridyl-1,3,4-oxadiazol-2-thiols were prepared according to the method of Wilder Smith *et al.* [5]. The thiols were converted into their sodio-derivatives which on treatment with ethyl bromoacetate, yielded the corresponding esters. The esters reacted with dry hydrazine to give the corresponding hydrazides. The thiosemicarbazides were prepared by treating the respective hydrazides with allyl isothiocyanate in acetonitrile. The salicylidene derivatives were prepared by condensing the hydrazides with salicylaldehyde in dry ethanol and the structures confirmed by micro-analysis, mass spectra, IR, and chemical studies.



Experimental

IR spectra (KBr discs) were determined on a Beckman IR4 instrument and mass spectra on an

*Department of Pharmacy, University of Strathclyde, George Street, Glasgow, U.K.

To whom inquires should be addressed.

A.C.J.Ms-9 instrument. The purity of analytical samples was determined by TLC on silica gel.

Ethyl- α -[5-(Pyridyl)-1,3,4-oxadiazol-2-ylthio]acetate (*I*; *R* = *OEt*).

5-(4-pyridyl)-1,3,4-oxadiazol-2-thiol (8.95 g) was dissolved in water containing sodium bicarbonate (4.2 g), and the solution filtered and evaporated *in vacuo*. The residue was treated with ethyl bromoacetate (8.35 g) in dry ethanol, and the mixture stirred for 1 h, and evaporated *in vacuo* to give a solid which was crystallized to yield the product (11.4g) mp 87-88° (hexane- benzene). IR 1735 (C=O), 1580, 1490 (pyridine), 1026, 740 cm⁻¹ (oxadiazole); mass *m/z* 265 M⁺. Aanal.Calc. for C₁₁H₁₁N₃O₂S: C, 49.81; H, 4.15; N, 15.85. Found: C 49.79; H, 4.10; N, 15.79%.

Ethyl- α -[5-(3-Pyridyl)-1,3,4-oxadiazol-2-ylthio] acetate (*I*; *R* = *OEt*).

Similarly, 5-(3-pyridyl)-1,3,4-exadiazol-2-thiol (8.9g) and ethyl bromoacetate (8.35 g) gave the product (11.5 g) mp 65-66° 750 cm⁻¹ (oxadiazole). Anal.Calc. for C₁₁H₁₁N₃O₂S: C, 49.81; H, 4.15; N, 15.85. Found: C, 49.80, H, 4.109; N, 15.75%.

Ethyl- α -[5-(2-pyridyl)-1,3,4-oxadiazol-2-ylthio] acetate (*I*; *R* = *OEt*).

Similarly, 5-(2-pyridyl)-1,3,4-oxadiazol-2-thiol (8.95%) and ethyl bromoacetate (8.35%) gave the product (12.1g) mp 43-45° (hexane-benzene). IR: 1745 (C=O) 1595, (pyridine), 1035, 760 cm⁻¹ (oxadiazole) Anal.Calc.for C₁₁H₁₁O₂S: C, 49.81; H, 4.15; N, 15.85. Found: C, 49.77; H, 4.08; N, 15.68%.

α -[5-(4-Pyridyl)-1,3,4-oxadiazol-2-ylthio] acethydrazide(*I*; *R* = *NHNH₂*).

Ethyl- α -[5-(4-pyridyl)1,3,4-oxadiazol-2-ylthio] acetate (16.9g) was dissolved in dry ethanol at 0°, dry hydrazine (2.0 g) added, and the mixture stirred at 0° for 2 h. The resulting solid was washed with dry ethanol and ether, filtered and crysallized to give the product (9.0g) mp 178-180° (DMF-H₂O). IR; 1675 (CONHNH₂), 1590, 1470 (pyridine), 1020, 730 cm⁻¹ (oxadiazole); mass *m/z* 251 M⁺. Anal.Calc. for C₉H₉N₅O₂S; C, 43.02; H, 3.58; N, 27.88. Found: C, 43.0; H, 3.50; N, 27.80%.

α -[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl-thio]acethydrazide (*I*; *R* = *NHNH₂*)

Similarly, ethyl- α -[5-(3-pyridyl)-1,3,4-oxadiazol-2-ylthio] acetate (10.6g) and dry hydrazine (2.2g) gave the product (7.94) mp 160-162° (methanol). IR; 1680 (CONHNH₂), 1592, 1490 (pyridine), 1035, 725 cm⁻¹ (oxadiazole). Anal.Calc. for C₉H₉N₅O₂S: C, 43.02, H: 3.58, N, 27.87 Found: C, 42.99; H, 3.52; N, 27.82%.

α -[5-(2-Pyridyl)-1,3,4-oxadiazol-2-ylthio] acethydrazide (*I*; *R* = *NHNH₂*).

Similarly, ethyl- α -[5-(2-pyridyl)-1,3,4-oxadiazol-2-ylthio] acetate (10.6 g) and dry hydrazine (2.2 g) gave the product (6.13 g) mp 168-170° (methanol). IR: 1682 (COHNHN₂) 1501, 1490 (pyridine), 1038, 742 cm⁻¹ (oxadiazole). Anal. Calc. for C₉H₉N₅O₂S: C, 43.02; H, 3.68; N, 27.87. Found: C, 42.95; H, 3.51; N, 27.67%.

4-Allyl-1-[5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio] acetyl]thiosemicarbazide (*I*; *R* = *NHNHCSNHCH₂CH=CH₂*).

α -[5-(4-Pyridyl)-1,3,4-oxadiazol-2-ylthio]acet hydrazide (0.5 g) was treated with freshly distilled allyl isothiocyanate (1 ml) in acetonitrile and the mixture refluxed for 2 h. The solvent was removed *in vacuo*, the residue washed with dry ether, filtered, and crystallized to give the product, (0.58 g) mp 155-157° (benzene-methanol). IR: 17500 (C=O), 1585, 1475 (pyridine) 1030, 1745 cm⁻¹ (oxadiazole). Anal.Calc. for C₁₃H₁₄N₆O₂S₂; C 44.57; H, 4.00; N, 23.98. Found: C, 44.51; H, 3.95; N, 23.90%.

4-Allyl-1-[5-(3-pyridyl)-1,3,4-oxadiazol-2-ylthio] acetyl] thiosemicarbazide (*I*; *R* = *NHNHCSNHCH₂CH₂*).

Similarly, α -[5-(3-pyridyl)-1,3,4-oxadiazol-2-ylthio] acethydrazide (0.5 g) and allyl isothiocyanate (1 gm) gave the product (0.5 g) mp 159-160° (benzene-methanol). IR; 1700 (CONHNH₂), 1601, 1495 (pyridine), 1037, 725 cm⁻¹ (oxadiazole). Anal.Calc. for C₁₃H₁₄N₆O₂S₂: C, 44.57; H, 4.00; N, 23.98. Found C, 44.49; H, 3.91; N, 23.88%.

4-Allyl-1-[5-(2-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiosemi-carbazide
($\therefore R = \text{NHNHCSNHCH}_3 = \text{CH}_2$).

Similarly, α -[5-(2-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide (0.5 g) and allyl isothiocyanate (1 gm) gave the product (0.488) mp 160-162° (benzene-methanol). IR: 1707 (CONHNH₂), 1600, 1498 (pyridine), 1031, 750 cm⁻¹ (oxadiazole). Anal.Calc. for C₁₃H₁₄N₆O₂S₂: C, 44.57, H, 4.00; N, 23.98. Found: C 44.50; H, 3.93; N, 23.79%.

N-Salicylidene- α -[5-(pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide I; R = NHN = CH-C₆H₄(OH)

α -[5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide (0.5 g) was condensed with salicylaldehyde (0.244 g) in dry ethanol on a boiling water bath for 30 min, and then set aside at room temperature for 3 h. The solid was filtered, washed with cold dry ether and crystallized to give the product (0.53 g) mp 190-191° (DMF-H₂O) IR: 1685 (C=O), 1590, 1480, 1470 (pyridine), 1035, 750, cm⁻¹ (oxadiazole). Anal.Calc. for C₁₆H₁₃N₅O₃S: C, 54.03; H, 3.66; N, 19.71. Found: C, 54.0, H, 3.59; N, 19.62%.

N-Salicylidene- α -[5-(3-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide I; R = NHN = CH-C₆H₄(OH)

Similarly, α -[5-(3-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide (0.244 g) and salicylaldehyde (0.244 g) gave the product (0.524 g) mp 180-185°

(methanol). IR; 1670 (V=O), 1601, 1599, 1495, 1480 (pyridine and benzene) 1032, 760, cm⁻¹ (oxadiazole) Anal.Calc. for C₁₆H₁₃N₅O₃S: C, 54.08; H, 3.66; N, 19.71. Found: C, 54.00; H, 3.59; N, 19.6%.

N-Salicylidene- α -[5-(2-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide (I.R = NHN = CHC₆H₄(OH).

Similarly, α -[5-2-pyridyl)-1,3,4-oxadiazol-2-ylthio]acetylthiohydrazide (0.5 g) and salicylaldehyde (0.244g) gave the product (0.5 g) mp 208-211° (methanol). IR: 1680 (C=O) 1600, 1595, 1485 (pyridine and benzene) and 1038, 770 cm⁻¹ (oxadiazole). Anal.Calc. for C₁₆H₁₃N₅O₃S: C, 54.08, H, 3.66; N, 19.71; Found: C, 54.02 H, 3.58, N, 19.59%.

References

1. I.Mir, M.T. Siddiqui and A.M. Comrie, *Tetrahedron*, **26**, 5235 (1970).
2. I. Mir, M.T. Siddiqui and A.M. Comrie, *J.Chem.Soc.(C)*: 2798 (1971).
3. I. Mir, M.T. Siddiqui and A.M. Comrie, *Sixth International Congress of Heterocycles Chemistry*, A14, (1977).
4. I. Mir, M.T. Siddiqui and A.M. Comrie *J.Pharm.Sci.* (in press).
5. A.E.W. Smith, Smith E. Brodhage, and G. Haukenes. *Arzneimittel Forsch.*, **12**, 275 (1962); *Chem.Abstr.*, **57**, 7256a (1962).